Back

Epidermal Growth Factor/c-Met receptor signalling crosstalk drives tunneling nanotube formation in A549 lung adenocarcinoma cells

Banerjee, S.; Elmeligy, A.; Awanis, G.; Cicovacki, N.; Scalcione, J.; Mccoll, J.; Leze, B.; Bidula, S.; Gavrilovic, J.; Warren, D.; Sobolewski, A.

2026-01-26 cancer biology
10.64898/2026.01.23.701283 bioRxiv
Show abstract

Tunneling nanotubes (TNTs) are actin-based cytoplasmic connections that can mediate intercellular transfer of various cellular cargo and have been implicated in cancer progression and chemoresistance. However, the signalling mechanisms driving their formation remain poorly understood. Given the frequent dysregulation of EGFR and c-Met signalling in non-small cell lung cancer (NSCLC), and prior evidence of TNTs in lung adenocarcinoma patient samples, we investigated the role of EGFR and c-Met receptor signalling crosstalk in TNT induction in A549 lung adenocarcinoma cells. Stimulation with EGF, HGF, or in combination induced a concentration dependent increase in the formation of TNTs. TNTs exhibited typical characteristics, including F-actin expression, non-adherence to the substratum and facilitated intercellular trafficking of lysosomes, mitochondria, and lipid vesicles. EGFR was identified as a novel component of TNTs, but had little co-localisation with the c-Met receptor. Co-stimulation with HGF and EGF did not produce consistent additive or synergistic effects on TNT formation, suggesting shared downstream signalling. Furthermore, although EGFR and c-Met inhibition blocked EGF- and HGF-induced TNTs respectively, inhibition of both receptors was required to suppress TNTs following dual HGF/EGF treatment. Interestingly, blocking the EGF receptor alongside c-Met resulted in a more potent inhibition of HGF-induced TNTs, indicating crosstalk. Furthermore, inhibition of downstream MEK and PI3K pathways reduced HGF- or EGF- induced TNT formation, but dual inhibition was required to completely block TNT formation in HGF+EGF co-stimulated cells. These findings reveal a novel convergence of EGFR and c-Met and their downstream MAPK/PI3K pathways in TNT regulation, which can have important clinical implications in combinatorial receptor and cell signalling pathway targeting in NSCLC.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
22.8%
2
Scientific Reports
3102 papers in training set
Top 17%
6.4%
3
Molecular Oncology
50 papers in training set
Top 0.1%
4.9%
4
Nature Communications
4913 papers in training set
Top 36%
4.2%
5
British Journal of Cancer
42 papers in training set
Top 0.4%
3.6%
6
Disease Models & Mechanisms
119 papers in training set
Top 0.5%
3.3%
7
Journal of Cell Science
353 papers in training set
Top 0.6%
3.1%
8
eLife
5422 papers in training set
Top 33%
2.4%
50% of probability mass above
9
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
2.1%
10
Molecular Cancer Research
42 papers in training set
Top 0.2%
1.9%
11
Cell Reports
1338 papers in training set
Top 22%
1.9%
12
The EMBO Journal
267 papers in training set
Top 1%
1.9%
13
Oncogene
76 papers in training set
Top 0.9%
1.9%
14
iScience
1063 papers in training set
Top 14%
1.7%
15
PLOS ONE
4510 papers in training set
Top 56%
1.5%
16
Cell Death Discovery
51 papers in training set
Top 0.7%
1.3%
17
Molecular Cancer
14 papers in training set
Top 0.5%
1.3%
18
Oncogenesis
12 papers in training set
Top 0.1%
1.2%
19
Frontiers in Oncology
95 papers in training set
Top 3%
1.1%
20
Life Science Alliance
263 papers in training set
Top 0.8%
1.1%
21
Acta Neuropathologica Communications
81 papers in training set
Top 0.9%
0.9%
22
Communications Biology
886 papers in training set
Top 18%
0.9%
23
Molecular Biology of the Cell
272 papers in training set
Top 2%
0.9%
24
Biomolecules
95 papers in training set
Top 2%
0.8%
25
Translational Oncology
18 papers in training set
Top 0.3%
0.8%
26
Oncotarget
15 papers in training set
Top 0.4%
0.8%
27
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
28 papers in training set
Top 0.5%
0.8%
28
PLOS Genetics
756 papers in training set
Top 15%
0.8%
29
Cancer Letters
32 papers in training set
Top 0.7%
0.8%
30
Journal of Cell Biology
333 papers in training set
Top 4%
0.8%